Stockreport

Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF complete response rates and a favorable safety profile, and has secured an oversubscribed US$160,000,000 private placement to support advancement into the Phase 3 RESCUE [Read more]